Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Stephen Harvey Zinner, M.D.

Concepts

This page shows the publications Stephen Zinner has written about Area Under Curve.
Connection Strength

1.396
  1. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to linezolid in an in vitro dynamic model. J Antimicrob Chemother. 2017 Nov 01; 72(11):3100-3107.
    View in: PubMed
    Score: 0.127
  2. Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations. Antimicrob Agents Chemother. 2013 Oct; 57(10):4956-62.
    View in: PubMed
    Score: 0.095
  3. Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model. Antimicrob Agents Chemother. 2012 Mar; 56(3):1223-8.
    View in: PubMed
    Score: 0.085
  4. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion. Int J Antimicrob Agents. 2008 Dec; 32(6):488-93.
    View in: PubMed
    Score: 0.068
  5. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window. Antimicrob Agents Chemother. 2008 Jun; 52(6):1924-8.
    View in: PubMed
    Score: 0.065
  6. Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones. Antimicrob Agents Chemother. 2005 Jul; 49(7):2642-7.
    View in: PubMed
    Score: 0.054
  7. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. Int J Antimicrob Agents. 2005 May; 25(5):409-13.
    View in: PubMed
    Score: 0.053
  8. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model. Int J Antimicrob Agents. 2004 Aug; 24(2):173-7.
    View in: PubMed
    Score: 0.051
  9. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother. 2004 Jul; 54(1):178-86.
    View in: PubMed
    Score: 0.050
  10. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination. Int J Antimicrob Agents. 2004 May; 23(5):451-6.
    View in: PubMed
    Score: 0.050
  11. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother. 2003 Oct; 52(4):616-22.
    View in: PubMed
    Score: 0.048
  12. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother. 2003 May; 47(5):1604-13.
    View in: PubMed
    Score: 0.047
  13. The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses. J Antimicrob Chemother. 2001 Dec; 48(6):821-6.
    View in: PubMed
    Score: 0.042
  14. Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships. Diagn Microbiol Infect Dis. 2001 Aug; 40(4):167-71.
    View in: PubMed
    Score: 0.041
  15. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. J Antimicrob Chemother. 2000 Nov; 46(5):725-32.
    View in: PubMed
    Score: 0.039
  16. Predicting the antistaphylococcal effects of daptomycin-rifampicin combinations in an in vitro dynamic model. J Antibiot (Tokyo). 2020 02; 73(2):101-107.
    View in: PubMed
    Score: 0.036
  17. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model. J Antimicrob Chemother. 1999 Apr; 43(4):483-90.
    View in: PubMed
    Score: 0.035
  18. Concentration-dependent enrichment of resistant Enterococcus faecium exposed to linezolid in an in vitro dynamic model. J Chemother. 2018 Oct - Dec; 30(6-8):364-370.
    View in: PubMed
    Score: 0.034
  19. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob Agents Chemother. 1998 Mar; 42(3):659-65.
    View in: PubMed
    Score: 0.033
  20. Time inside the mutant selection window as a predictor of staphylococcal resistance to linezolid. J Antibiot (Tokyo). 2018 05; 71(5):514-521.
    View in: PubMed
    Score: 0.032
  21. Species differences in ciprofloxacin resistance among Gram-negative bacteria: can "anti-mutant" ratios of the area under the concentration-time curve to the MIC be achieved clinically? J Chemother. 2017 Dec; 29(6):351-357.
    View in: PubMed
    Score: 0.031
  22. Predicting effects of antibiotic combinations using MICs determined at pharmacokinetically derived concentration ratios: in vitro model studies with linezolid- and rifampicin-exposed Staphylococcus aureus. J Chemother. 2017 Oct; 29(5):267-273.
    View in: PubMed
    Score: 0.030
  23. Net effect of inoculum size on antimicrobial action of ampicillin-sulbactam: studies using an in vitro dynamic model. Antimicrob Agents Chemother. 1997 Jan; 41(1):7-12.
    View in: PubMed
    Score: 0.030
  24. Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models. Antimicrob Agents Chemother. 2015 Dec 07; 60(3):1208-15.
    View in: PubMed
    Score: 0.028
  25. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration. J Antimicrob Chemother. 2016 Mar; 71(3):678-84.
    View in: PubMed
    Score: 0.028
  26. The antistaphylococcal pharmacodynamics of linezolid alone and in combination with doxycycline in an in vitro dynamic model. J Chemother. 2011 Jun; 23(3):140-4.
    View in: PubMed
    Score: 0.020
  27. Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. Int J Antimicrob Agents. 2009 Mar; 33(3):251-4.
    View in: PubMed
    Score: 0.017
  28. Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother. 2008 Nov; 62(5):1065-9.
    View in: PubMed
    Score: 0.017
  29. Concentration-response relationships as a basis for choice of the optimal endpoints of the antimicrobial effect: daptomycin and vancomycin pharmacodynamics with staphylococci in an in vitro dynamic model. Int J Antimicrob Agents. 2007 Feb; 29(2):165-9.
    View in: PubMed
    Score: 0.015
  30. Comparative pharmacodynamics of telithromycin and clarithromycin with Streptococcus pneumoniae and Staphylococcus aureus in an in vitro dynamic model: focus on clinically achievable antibiotic concentrations. Int J Antimicrob Agents. 2005 Sep; 26(3):197-204.
    View in: PubMed
    Score: 0.014
  31. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. J Antimicrob Chemother. 2002 Oct; 50(4):533-9.
    View in: PubMed
    Score: 0.011
  32. Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model. Int J Antimicrob Agents. 2002 Sep; 20(3):201-5.
    View in: PubMed
    Score: 0.011
  33. Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflecting comparative fluoroquinolone anti-pseudomonal pharmacodynamics in an in vitro dynamic model. Int J Antimicrob Agents. 2002 Jul; 20(1):44-9.
    View in: PubMed
    Score: 0.011
  34. Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. Chemotherapy. 2002; 48(6):275-9.
    View in: PubMed
    Score: 0.011
  35. Relationships of the area under the curve/MIC ratio to different integral endpoints of the antimicrobial effect: gemifloxacin pharmacodynamics in an in vitro dynamic model. Antimicrob Agents Chemother. 2001 Mar; 45(3):927-31.
    View in: PubMed
    Score: 0.010
  36. Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses. Int J Antimicrob Agents. 2000 Dec; 16(4):407-14.
    View in: PubMed
    Score: 0.010
  37. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. Antimicrob Agents Chemother. 2000 Apr; 44(4):879-84.
    View in: PubMed
    Score: 0.009
  38. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. Antimicrob Agents Chemother. 1999 Mar; 43(3):498-502.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.